HCWB — HCW Biologics Inc

HCW Biologics Inc (HCWB) is a biotechnology company listed on NASDAQ. It is led by Hing C. Wong Ph.D., based in 2929 North Commerce Parkway, Miramar, FL, United States, 33025, with about 35 employees. HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, an immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Net income was -$4.6M. HCWB currently screens at market cap $14.2M.

Use this HCWB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the HCWB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the HCWB SEC filings page. Lician reads the product cache first so this HTML stays unique to HCW Biologics Inc even when a live quote feed is slow.